Table 1. Patient characteristics . FtoM... | American Society of Hematology

Table 1.

Patient characteristics

	FtoM (n = 315)			MtoF (n = 260)			Matched (n = 557)
	BM, n	PBSCs, n	P	BM, n	PBSCs, n	P	BM, n	PBSCs, n	P
Patient age, y			.80			.59			.45
<50	57	128	.80	54	109		118	242
≥50	38	92		36	61		58	139
Donor age, y			.71			1.00			.35
<50	59	131		62	116		116	234
≥50	36	89		28	54		60	146
Performance status			1.00			.23			1.00
0-1	92	211		88	159		169	365
2-4	3	9		2	10		7	16
CMV serostatus			.01			.52			.36
No	32	44		16	38		40	73
Yes	57	158		69	127		127	287
Disease			.18			.25			.69
AML	52	102		39	80		78	161
ALL	23	59		26	43		41	96
Lymphoma	6	31		10	30		31	78
CML, MPD, MDS	14	28		15	17		26	46
rDRI			.64			.33			.41
Low	14	24		7	18		20	51
Intermediate	73	175		78	135		147	304
High	8	18		4	15		6	22
HCT-CI			.57			.55			.11
0	64	134		66	113		128	244
1-2	21	55		14	34		35	86
≥3	9	28		10	23		13	47
GVHD prophylaxis			.07			.03			.01
Cyclosporine based	78	154		76	122		135	266
Tacrolimus based	14	58		12	45		35	112
Other	3	8		2	3		6	3
Conditioning			.66			.65			.59
Cyclophosphamide + TBI	42	88		37	68		76	148
Busulfan + cyclophosphamide	14	35		15	34		30	57
Other MAC	20	42		11	29		22	66
Fludarabine RIC	16	51		24	34		43	97
Other RIC	3	4		3	5		5	13
TBI			1.00			.79			.11
No	40	92		37	73		61	159
Yes	55	128		53	97		115	222

	FtoM (n = 315)			MtoF (n = 260)			Matched (n = 557)
	BM, n	PBSCs, n	P	BM, n	PBSCs, n	P	BM, n	PBSCs, n	P
Patient age, y			.80			.59			.45
<50	57	128	.80	54	109		118	242
≥50	38	92		36	61		58	139
Donor age, y			.71			1.00			.35
<50	59	131		62	116		116	234
≥50	36	89		28	54		60	146
Performance status			1.00			.23			1.00
0-1	92	211		88	159		169	365
2-4	3	9		2	10		7	16
CMV serostatus			.01			.52			.36
No	32	44		16	38		40	73
Yes	57	158		69	127		127	287
Disease			.18			.25			.69
AML	52	102		39	80		78	161
ALL	23	59		26	43		41	96
Lymphoma	6	31		10	30		31	78
CML, MPD, MDS	14	28		15	17		26	46
rDRI			.64			.33			.41
Low	14	24		7	18		20	51
Intermediate	73	175		78	135		147	304
High	8	18		4	15		6	22
HCT-CI			.57			.55			.11
0	64	134		66	113		128	244
1-2	21	55		14	34		35	86
≥3	9	28		10	23		13	47
GVHD prophylaxis			.07			.03			.01
Cyclosporine based	78	154		76	122		135	266
Tacrolimus based	14	58		12	45		35	112
Other	3	8		2	3		6	3
Conditioning			.66			.65			.59
Cyclophosphamide + TBI	42	88		37	68		76	148
Busulfan + cyclophosphamide	14	35		15	34		30	57
Other MAC	20	42		11	29		22	66
Fludarabine RIC	16	51		24	34		43	97
Other RIC	3	4		3	5		5	13
TBI			1.00			.79			.11
No	40	92		37	73		61	159
Yes	55	128		53	97		115	222

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CMV, cytomegalovirus; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; RIC, reduced-intensity conditioning; TBI, total-body irradiation.

View Large

This Feature Is Available To Subscribers Only